Key Takeaways
- Vetigenics closed a $6 million seed round, enabling the advancement of clinical-stage programs and scaling of operations.
- Two significant trials targeting canine cancers are nearing completion, with promising results expected for both therapies.
- The company has formed a new board of directors comprised of industry leaders to guide its future growth and initiatives.
Vetigenics Advances in Animal Health Biotechnology
Vetigenics, a clinical-stage animal health biotechnology firm focused on antibody therapeutics for pets, has made significant strides in the past year, highlighted by the completion of a $6 million seed financing round. This funding enables the company to accelerate its growth and enhance its clinical-stage programs, which are essential for progressing toward pivotal trials, advancing preclinical developments, and scaling up operations and manufacturing.
Among the company’s achievements are two key clinical trials targeting canine cancers. The first, VGS-001 (anti-cCTLA4), is an antibody therapy combined with palliative radiation aimed at treating oral melanoma in dogs. This trial has reached completion, with positive results expected to be published in 2025. The second trial, VGS-002 (anti-cPD1), involves a monotherapy for dogs with urothelial carcinoma and is nearing completion, with anticipated promising results set to be released later this year.
Beyond cancer treatment, Vetigenics is also pushing forward with preclinical programs that target autoimmune diseases, obesity, and allergies in pets. Notably, the VGS-003 (anti-cCD19 mAb) candidate is in the evaluation stage and is projected to enter clinical trials by the end of 2025. These advancements aim to address significant unmet needs in companion animal care, positioning Vetigenics as a leader in innovative pet health solutions.
The company has also established a new board of directors, comprising industry experts to steer its strategy and growth. Members include Chand Khanna, DVM, PhD, known for his work in comparative oncology; Stephen Lesser, JD, MBA, a strategic advisor in biotechnology; Caleb Frankel, VMD, an innovator in veterinary technology; and Adriann Sax, MBA, who serves as President and CEO of Vetigenics.
With a robust pipeline of clinical trials, strategic partnerships, and an expanded team of experts, Vetigenics is set to transform pet health further in 2025. The company remains dedicated to improving the lives of pets through progressive research and development initiatives.
Key stakeholders express strong support for Vetigenics’ vision. CEO Adriann Sax emphasized the confidence investors have in the company’s ability to effect substantial progress through efficient capital use. Clinical investigator Nicola Mason highlighted the significant unmet needs in veterinary cancers that Vetigenics’ therapies aim to address. Finally, co-founder Don Siegel noted the unique capabilities of the CANIBODY library in generating novel antibodies for challenging therapeutic targets.
The content above is a summary. For more details, see the source article.